Xiangxiang Zeng1, Siyi Zhu1, Xiangrong Liu1, Yadi Zhou2, Ruth Nussinov3,4, Feixiong Cheng2,5,6. 1. Department of Computer Science, Xiamen University, Xiamen 361005, China. 2. Genomic Medicine Institute, Lerner Research Institute, Cleveland Clinic, Cleveland, OH 44195, USA. 3. Computational Structural Biology Section, Basic Science Program, Frederick National Laboratory for Cancer Research, National Cancer Institute at Frederick, Frederick, MD 21702, USA. 4. Department of Human Molecular Genetics and Biochemistry, Sackler School of Medicine, Tel Aviv University, Tel Aviv 69978, Israel. 5. Department of Molecular Medicine, Cleveland Clinic Lerner College of Medicine, Case Western Reserve University, Cleveland, OH 44195, USA. 6. Case Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, OH 44106, USA.
Abstract
MOTIVATION: Traditional drug discovery and development are often time-consuming and high risk. Repurposing/repositioning of approved drugs offers a relatively low-cost and high-efficiency approach toward rapid development of efficacious treatments. The emergence of large-scale, heterogeneous biological networks has offered unprecedented opportunities for developing in silico drug repositioning approaches. However, capturing highly non-linear, heterogeneous network structures by most existing approaches for drug repositioning has been challenging. RESULTS: In this study, we developed a network-based deep-learning approach, termed deepDR, for in silico drug repurposing by integrating 10 networks: one drug-disease, one drug-side-effect, one drug-target and seven drug-drug networks. Specifically, deepDR learns high-level features of drugs from the heterogeneous networks by a multi-modal deep autoencoder. Then the learned low-dimensional representation of drugs together with clinically reported drug-disease pairs are encoded and decoded collectively via a variational autoencoder to infer candidates for approved drugs for which they were not originally approved. We found that deepDR revealed high performance [the area under receiver operating characteristic curve (AUROC) = 0.908], outperforming conventional network-based or machine learning-based approaches. Importantly, deepDR-predicted drug-disease associations were validated by the ClinicalTrials.gov database (AUROC = 0.826) and we showcased several novel deepDR-predicted approved drugs for Alzheimer's disease (e.g. risperidone and aripiprazole) and Parkinson's disease (e.g. methylphenidate and pergolide). AVAILABILITY AND IMPLEMENTATION: Source code and data can be downloaded from https://github.com/ChengF-Lab/deepDR. SUPPLEMENTARY INFORMATION: Supplementary data are available online at Bioinformatics.
MOTIVATION: Traditional drug discovery and development are often time-consuming and high risk. Repurposing/repositioning of approved drugs offers a relatively low-cost and high-efficiency approach toward rapid development of efficacious treatments. The emergence of large-scale, heterogeneous biological networks has offered unprecedented opportunities for developing in silico drug repositioning approaches. However, capturing highly non-linear, heterogeneous network structures by most existing approaches for drug repositioning has been challenging. RESULTS: In this study, we developed a network-based deep-learning approach, termed deepDR, for in silico drug repurposing by integrating 10 networks: one drug-disease, one drug-side-effect, one drug-target and seven drug-drug networks. Specifically, deepDR learns high-level features of drugs from the heterogeneous networks by a multi-modal deep autoencoder. Then the learned low-dimensional representation of drugs together with clinically reported drug-disease pairs are encoded and decoded collectively via a variational autoencoder to infer candidates for approved drugs for which they were not originally approved. We found that deepDR revealed high performance [the area under receiver operating characteristic curve (AUROC) = 0.908], outperforming conventional network-based or machine learning-based approaches. Importantly, deepDR-predicted drug-disease associations were validated by the ClinicalTrials.gov database (AUROC = 0.826) and we showcased several novel deepDR-predicted approved drugs for Alzheimer's disease (e.g. risperidone and aripiprazole) and Parkinson's disease (e.g. methylphenidate and pergolide). AVAILABILITY AND IMPLEMENTATION: Source code and data can be downloaded from https://github.com/ChengF-Lab/deepDR. SUPPLEMENTARY INFORMATION: Supplementary data are available online at Bioinformatics.
Authors: Guy Van Camp; Anja Flamez; Bernard Cosyns; Caroline Weytjens; Luc Muyldermans; Michel Van Zandijcke; Johan De Sutter; Patrick Santens; Pierre Decoodt; Christian Moerman; Danny Schoors Journal: Lancet Date: 2004-04-10 Impact factor: 79.321
Authors: Peter De Deyn; Dilip V Jeste; Rene Swanink; Dusan Kostic; Christopher Breder; William H Carson; Taro Iwamoto Journal: J Clin Psychopharmacol Date: 2005-10 Impact factor: 3.153
Authors: Peter Paul De Deyn; Annemieke F J Drenth; Berry P Kremer; Richard C Oude Voshaar; Debby Van Dam Journal: Expert Opin Pharmacother Date: 2013-01-28 Impact factor: 3.889
Authors: Travers Ching; Daniel S Himmelstein; Brett K Beaulieu-Jones; Alexandr A Kalinin; Brian T Do; Gregory P Way; Enrico Ferrero; Paul-Michael Agapow; Michael Zietz; Michael M Hoffman; Wei Xie; Gail L Rosen; Benjamin J Lengerich; Johnny Israeli; Jack Lanchantin; Stephen Woloszynek; Anne E Carpenter; Avanti Shrikumar; Jinbo Xu; Evan M Cofer; Christopher A Lavender; Srinivas C Turaga; Amr M Alexandari; Zhiyong Lu; David J Harris; Dave DeCaprio; Yanjun Qi; Anshul Kundaje; Yifan Peng; Laura K Wiley; Marwin H S Segler; Simina M Boca; S Joshua Swamidass; Austin Huang; Anthony Gitter; Casey S Greene Journal: J R Soc Interface Date: 2018-04 Impact factor: 4.293
Authors: Brent M Kuenzi; Jisoo Park; Samson H Fong; Kyle S Sanchez; John Lee; Jason F Kreisberg; Jianzhu Ma; Trey Ideker Journal: Cancer Cell Date: 2020-10-22 Impact factor: 31.743